CYDX (Cyduct Diagnostics) Marketable Securities: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cyduct Diagnostics Marketable Securities?

Cyduct Diagnostics CYDX +9.34% Marketable Securities is $0.00 Mil as of Jun. 2026.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Cyduct Diagnostics's Marketable Securities for the quarter that ended in Jun. 2026 was $0.00 Mil.

Cyduct Diagnostics  (OTCPK:CYDX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Cyduct Diagnostics Marketable Securities Related Terms

Cyduct Diagnostics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Cyduct Diagnostics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyduct Diagnostics Marketable Securities Chart

Cyduct Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cyduct Diagnostics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cyduct Diagnostics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Cyduct Diagnostics (CYDX) has a Marketable Securities of $0.00 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Cyduct Diagnostics and its competitors.
Is Cyduct Diagnostics' Marketable Securities too high?
Cyduct Diagnostics' current Marketable Securities is $0.00 Mil.
How does Cyduct Diagnostics' Marketable Securities compare to SECI and QTXB?
Cyduct Diagnostics' Marketable Securities of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Cyduct Diagnostics and its competitors. Cyduct Diagnostics's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyduct Diagnostics stock overvalued right now?
Cyduct Diagnostics (CYDX) has a current Marketable Securities of $0.00 Mil. The current Marketable Securities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Cyduct Diagnostics (CYDX), the current Marketable Securities is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cyduct Diagnostics Business Description

Address 1698 Post Road East, Suite 1A, Westport, CT, USA, 06880
Cyduct Diagnostics Inc. is a clinical-stage medical diagnostics company based in the United States. It develops technologies for the early assessment and detection of breast cancer, principally through its MammoView platform, a single-use device designed to screen, assess, monitor, and support treatment of changes in breast health. The company also markets a line of branded surgical instruments, including endoscopes and handheld instruments for minimally invasive surgery, manufactured by third parties to its specifications. These products are sold under the Solos Endoscopy brand. Cyduct Diagnostics serves hospitals, surgical centers, and healthcare providers, generating revenue primarily through product sales of its diagnostic devices and surgical instruments. The company operates mainly in the United States and remains focused on expanding its breast health diagnostics portfolio.